Stockscreener 앱 받기
6.85
0.86%
-0.03
전일 마감가:
$6.88
열려 있는:
$6.77
하루 거래량:
3,326
Relative Volume:
0.02
시가총액:
$59.40M
수익:
$137.27M
순이익/손실:
$-123.57M
주가수익비율:
-0.6256
EPS:
-10.95
순현금흐름:
$-102.89M
1주 성능:
+19.04%
1개월 성능:
+8.10%
6개월 성능:
+21.80%
1년 성능:
-34.76%
1일 변동 폭
$6.77
$6.98
1주일 범위
$5.32
$7.90
52주 변동 폭
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.85 | 64.86M | 137.27M | -123.57M | -102.89M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
384.68 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.60 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.14 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
718.94 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
330.14 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last? - Nasdaq
Smart tools for monitoring Karyopharm Therapeutics Inc.’s price actionWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Karyopharm increases authorized shares, approves reverse split - MSN
Ideas Watch: Can Karyopharm Therapeutics Inc disrupt its industryMarket Sentiment Review & Weekly Top Gainers Alerts - خودرو بانک
Karyopharm Therapeutics Inc.(NasdaqGS: KPTI) dropped from S&P Global BMI Index - MarketScreener
Market Overview: Is Karyopharm Therapeutics Incs ROIC above industry average2025 Stock Rankings & Capital Efficiency Focused Ideas - خودرو بانک
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $34.00 Consensus Price Target from Analysts - MarketBeat
Death Cross: Is Karyopharm Therapeutics Incs growth already priced inCEO Change & Fast Exit Strategy with Risk Control - khodrobank.com
Is Karyopharm Therapeutics Inc. stock entering bullish territoryJuly 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - newser.com
Risk Check: Can Bread Financial Holdings Inc continue delivering strong returnsLayoff News & Free Accurate Trade Setup Notifications - خودرو بانک
Aug Rallies: Is Cartesian Growth Corporation Equity Warrant forming a double bottomEarnings Trend Report & Safe Entry Trade Signal Reports - khodrobank.com
Insider Buy: Will Karyopharm Therapeutics Inc. benefit from rate cuts2025 Key Highlights & Entry Point Confirmation Signals - خودرو بانک
Karyopharm CEO Paulson sells $8k in shares By Investing.com - Investing.com South Africa
Karyopharm therapeutics EVP Cheng sells $2089 in stock By Investing.com - Investing.com Canada
Karyopharm Therapeutics Board Member Resigns Amid Career Shift - MSN
Karyopharm therapeutics EVP Cheng sells $2089 in stock - Investing.com India
Karyopharm CEO Paulson sells $8k in shares - Investing.com India
Aug Wrap: Is SLM Corporation part of any major indexWeekly Market Report & Low Risk Profit Maximizing Plans - خودرو بانک
Gap Down: Is Karyopharm Therapeutics Inc gaining market share2025 Investor Takeaways & Technical Pattern Based Signals - خودرو بانک
Volatility Watch: What are Karyopharm Therapeutics Inc.’s recent SEC filings showingQuarterly Profit Report & AI Based Trade Execution Alerts - خودرو بانک
Entry Recap: Will Karyopharm Therapeutics Inc. benefit from current market trends2025 Top Gainers & Stock Portfolio Risk Control - خودرو بانک
Wall Street Recap: Is Karyopharm Therapeutics Inc gaining market shareJuly 2025 Action & Fast Gain Stock Tips - خودرو بانک
Volume Report: What are Karyopharm Therapeutics Inc.’s recent SEC filings showingWeekly Trade Report & Reliable Trade Execution Plans - khodrobank.com
These biotechs are in the market for a buyer - The Business Journals
Income Plays: Will Karyopharm Therapeutics Inc outperform its industry peersTrade Analysis Summary & Short-Term Swing Trade Alerts - خودرو بانک
Karyopharm Therapeutics Inc. $KPTI Position Reduced by Adage Capital Partners GP L.L.C. - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65% - simplywall.st
Karyopharm concludes enrolment in Phase III myelofibrosis treatment trial - Yahoo Finance
Karyopharm completes enrollment in phase 3 myelofibrosis trial By Investing.com - Investing.com Australia
Karyopharm completes enrollment in phase 3 myelofibrosis trial - Investing.com India
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis - Citizen Tribune
Karyopharm announces completion of enrollment in the phase 3 SENTRY trial in myelofibrosis - MarketScreener
Published on: 2025-09-08 20:44:00 - beatles.ru
Karyopharm Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsWatch List & Technical Analysis for Trade Confirmation - beatles.ru
Palo Alto Investors LP Cuts Stock Holdings in Karyopharm Therapeutics Inc. $KPTI - MarketBeat
Birchview Capital LP Trims Holdings in Karyopharm Therapeutics Inc. $KPTI - MarketBeat
Is Karyopharm Therapeutics Inc. gaining market share2025 Earnings Surprises & Technical Analysis for Trade Confirmation - classian.co.kr
Analyzing recovery setups for Karyopharm Therapeutics Inc. investorsJuly 2025 Rallies & Verified Momentum Stock Ideas - Newser
Multi factor analysis applied to Karyopharm Therapeutics Inc.2025 Support & Resistance & Daily Profit Maximizing Trade Tips - Newser
Will Karyopharm Therapeutics Inc. benefit from current market trendsMarket Weekly Review & Daily Stock Trend Reports - خودرو بانک
Can Karyopharm Therapeutics Inc. recover in the next quarterJuly 2025 Final Week & Daily Profit Focused Stock Screening - Newser
Is Karyopharm Therapeutics Inc. benefiting from innovation trendsJuly 2025 Trends & Free Community Supported Trade Ideas - خودرو بانک
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Karyopharm Therapeutics Inc. stock daily chart insights2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Is Karyopharm Therapeutics Inc. trending in predictive chart modelsMarket Risk Report & Fast Moving Stock Watchlists - Newser
What candlestick patterns are forming on Karyopharm Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Alerts - Newser
Using data tools to time your Karyopharm Therapeutics Inc. exitJuly 2025 Setups & Weekly Watchlist for Hot Stocks - Newser
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.20%
0.35%
자본화:
|
볼륨(24시간):